Repligen Corporation (RGEN)
NASDAQ: RGEN · IEX Real-Time Price · USD
123.81
-3.82 (-2.99%)
At close: Jul 19, 2024, 4:00 PM
123.91
+0.10 (0.08%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Repligen Employees
Repligen had 1,783 employees as of December 31, 2023. The number of employees decreased by 242 or -11.95% compared to the previous year.
Employees
1,783
Change (1Y)
-242
Growth (1Y)
-11.95%
Revenue / Employee
$340,690
Profits / Employee
$8,324
Market Cap
6.92B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,783 | -242 | -11.95% |
Dec 31, 2022 | 2,025 | 173 | 9.34% |
Dec 31, 2021 | 1,852 | 724 | 64.18% |
Dec 31, 2020 | 1,128 | 367 | 48.23% |
Dec 31, 2019 | 761 | 213 | 38.87% |
Dec 31, 2018 | 548 | 72 | 15.13% |
Dec 31, 2017 | 476 | 240 | 101.69% |
Dec 31, 2016 | 236 | 68 | 40.48% |
Dec 31, 2015 | 168 | 32 | 23.53% |
Dec 31, 2014 | 136 | 20 | 17.24% |
Dec 31, 2013 | 116 | -4 | -3.33% |
Dec 31, 2012 | 120 | -17 | -12.41% |
Dec 31, 2011 | 137 | 69 | 101.47% |
May 6, 2010 | 68 | -1 | -1.45% |
May 31, 2009 | 69 | 13 | 23.21% |
May 27, 2008 | 56 | 11 | 24.44% |
Jun 30, 2007 | 45 | 2 | 4.65% |
Jun 6, 2006 | 43 | 6 | 16.22% |
Jun 7, 2005 | 37 | -3 | -7.50% |
Jun 7, 2004 | 40 | -4 | -9.09% |
May 15, 2003 | 44 | 5 | 12.82% |
May 15, 2002 | 39 | -1 | -2.50% |
May 15, 2001 | 40 | 13 | 48.15% |
May 15, 2000 | 27 | 3 | 12.50% |
May 15, 1999 | 24 | 0 | - |
May 29, 1998 | 24 | 4 | 20.00% |
May 15, 1997 | 20 | 5 | 33.33% |
Jun 14, 1996 | 15 | -89 | -85.58% |
Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Penumbra | 4,200 |
Jazz Pharmaceuticals | 2,800 |
Tempus AI | 1,952 |
Exelixis | 1,310 |
Ionis Pharmaceuticals | 927 |
Ascendis Pharma | 879 |
Blueprint Medicines | 655 |
Cytokinetics | 423 |
RGEN News
- 6 days ago - Repligen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 25 days ago - This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
- 4 weeks ago - Top 3 Health Care Stocks That Could Blast Off In June - Benzinga
- 5 weeks ago - Repligen Announces CEO Transition Plan - GlobeNewsWire
- 6 weeks ago - Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing - Business Wire
- 2 months ago - Repligen Corporation to Present at Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - Repligen Corporation to Present at Upcoming May Investor Conferences - GlobeNewsWire
- 2 months ago - Repligen Reports First Quarter 2024 Financial Results - GlobeNewsWire